Volume | 2,168,581 |
|
|||||
News | - | ||||||
Day High | 63.48 | Low High |
|||||
Day Low | 60.37 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
EXACT Sciences Corporation | EXAS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
62.84 | 60.37 | 63.48 | 60.96 | 63.48 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
31,685 | 2,168,581 | $ 61.45 | $ 133,254,156 | - | 56.05 - 100.77 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:36:09 | formt | 300 | $ 60.96 | USD |
EXACT Sciences (EXAS) Options Flow Summary
EXACT Sciences Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.07B | 181.53M | - | 2.58B | -204.15M | -1.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
EXACT Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EXAS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 72.80 | 73.095 | 60.37 | 65.49 | 2,644,344 | -11.84 | -16.26% |
1 Month | 62.37 | 79.62 | 60.25 | 69.97 | 3,276,473 | -1.41 | -2.26% |
3 Months | 64.79 | 79.62 | 56.05 | 64.74 | 2,530,653 | -3.83 | -5.91% |
6 Months | 65.81 | 79.62 | 56.05 | 65.42 | 2,039,880 | -4.85 | -7.37% |
1 Year | 64.52 | 100.77 | 56.05 | 72.43 | 1,826,900 | -3.56 | -5.52% |
3 Years | 128.73 | 140.18 | 29.27 | 68.72 | 1,927,232 | -67.77 | -52.65% |
5 Years | 92.00 | 159.54 | 29.27 | 80.88 | 1,901,402 | -31.04 | -33.74% |
EXACT Sciences Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening. |